Ganoderma lucidum: A potential for biotechnological production of anti-cancer and immunomodulatory drugs

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 3, 2013, Pages 255-287

  Boh, Bojana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Anti cancer; Ganoderma lucidum; Immunomodulation; Polysaccharides; Proteins; Triterpenes

Indexed keywords

AMINO ACID; ANDROGEN; APPLANOXIDIC ACID A (20E) 15 ALPHA HYDROXY 7 ALPHA 8 ALPHA EPOXY 3 11 23 TRIOXO 5 ALPHA LANOSTA 9(11) 20 DIEN 26 OIC ACID; BETA 1, 6 GLUCAN; BETA 1,3 GLUCAN; CHOLESTEROL ESTERASE; FRUCTOSE; GALACTOSE; GAMMA INTERFERON; GANODERAL A (24E) 3 OXO 5 ALPHA LANOSTA 7 9(11) 24 TRIENE 26 AL; GANODERENIC ACID A (20E) 7 BETA 15 ALPHA DIHYDROXY 3 11 23 TRIOXO 5 ALPHA LANOSTA 8 20 DIEN 26 OIC ACID; GANODERIC ACID F 12 BETA ACETOXY 3 7 11 15 23 PENTAOXO 5 ALPHA LANOST 8 EN 26 OIC ACID; GANODERMA LUCIDUM EXTRACT; GANODERMIC ACID R (24E)3 ALPHA 15 ALPHA DIACETOXY 5 ALPHA LANOSTA 7 9(11) 24 TRIENE 26 OIC ACID; GANODEROL B GANODERMADIOL 5 ALPHA LANOSTA 7 9(11) 24 TRIENE 3 BETA 26 DIOL; GANOLUCIDIC ACID A 15 ALPHA HYDROXY 3 11 23 TRIOXO 5 ALPHA LANOST 8 EN 26 OIC ACID; GLUCOSE; GLYCOPEPTIDE; INTERLEUKIN 1; LUCIDENIC ACID D1 4 4 14 ALPHA TRIMETHYL 3 7 11 12 15 PENTAOXO 5 ALPHA CHOL 8 EN 24 OIC ACID; LUCIDONE C 3 BETA 7 BETA DIHYDROXY 4 4 14 ALPHA TRIMETHYL 11 15 20 TRIOXO 5 ALPHA PREGN 8 ENE; MANNOSE; MATRIX METALLOPROTEINASE; POLYSACCHARIDE; PROTEIN; PROTEOGLYCAN; RHAMNOSE; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; BIOMASS PRODUCTION; CANCER INHIBITION; COLUMN CHROMATOGRAPHY; CYTOTOXICITY; DOWN REGULATION; FRUITING BODY; FUNGUS SPORE; GERMINATION; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INFRARED SPECTROSCOPY; LIVER PROTECTION; LIVER TOXICITY; MYCELIUM; NEOPLASM; NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PURIFICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; SURVIVAL; THROMBOCYTE AGGREGATION; TUMOR INVASION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUSTRIAL MICROBIOLOGY; PATENTS AS TOPIC; REISHI;

EID: 84888041787     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574891X113089990036     Document Type: Article

References (276)

1. Boh B, Berovic M. Ganoderma lucidum Production of Pharmaceuticals. In: Liong MT, Ed. Bioprocess Sciences and Technology: Biochemistry Research Trends. Hauppauge, Nova Science Publishers, 2011, pp. 233-68.
2. Zhou XW, Su KQ, Zhang YM. Applied modern biotechnology for cultivation of Ganoderma and development of their products. Appl Microbiol Biotechnol 2012; 93: 941-63.
3. Web of Science: Advanced search. Available at: http://apps. webofknowledge. com/(Accessed on: July 30, 2012).
4. Espacenet: Advanced search. Available at: http://worldwide. espacenet. com/advancedSearch?locale=en_EP (Accessed on: July 30, 2012).
5. Stamets P. Ganoderma lucidum (Wm. Curtis: Fries) Karsten. In: Growing Gourmet and Medicinal Mushrooms. Berkeley, Ten Speed Press, 2000, pp. 352-66.
6. Shigeru, Y. Cultivation of Reishi. JP3083521 (1991).
7. Hitoshi, N. Mycelial extract of Ganoderma lucidum and production thereof. JP60149369 (1985).
8. Li, R., Chen, Y., Suo, J. Method for production of Ganoderma lucidum mycelium. CN1099217 (1995).
9. Toshio, M. Production of high purity mycelium of Ganoderma lucidum. JP10066535 (1998).
10. Habijanic J, Berovic M. The relevance of solid-state substrate moisturing on Ganoderma lucidum biomass cultivation. Food Technol Biotechnol 2000; 38: 225-8.
11. Habjanic, J., Berovic, M. Process of cultivation of fungus Ganoderma lucidum on a solid cultivation substrate. SI20923 (2002).
12. Li, P. J., Shen, C. G. Method for propagating fungi using solid state fermentation. US6558943 (2003).
13. Kohlmünzer S, Wegiel J, Sitarz J. Polysaccharides in mycelial culture of Ganoderma applanatum (Pers.). Pat Herba Hung 1989; 28, 87-94.
14. Fang QH, Zhong JJ. Effect of initial pH on production of ganoderic acid and polysaccharide by submerged fermentation of Ganoderma lucidum. Process Biochem 2002; 37: 769-74.
15. Fang QH, Zhong JJ. Submerged fermentation of higher fungus Ganoderma lucidum for production of valuable bioactive metabolites-ganoderic acid and polysaccharide, Biochem Eng J 2002; 10: 61-5.
16. Tang YJ, Zhong JJ. Fed-batch fermentation of Ganoderma lucidum for hyperproduction of polysaccharide and ganoderic acid. Enzyme Microb Technol 2002; 31: 20-8.
17. Tang YJ, Zhong JJ. Role of oxygen supply in submerged fermentation of Ganoderma lucidum for production of Ganoderma polysaccharide and ganoderic acid. Enzyme Microb Technol 2003; 32: 478-84.
18. Xu P, Ding ZY, Qian Z, Zhao CX, Zhang KC. Improved production of mycelial biomass and ganoderic acid bysubmerged culture of Ganoderma lucidum SB97 using complex media. Enzyme Microb Technol 2008; 42: 325-31.
19. Tang YJ, Zhang W Zhong JJ. Performance analyses of a pH-shift and DOT-shift integrated fed-batch fermentation process for the production of ganoderic acid and Ganoderma polysaccharides by medicinal mushroom Ganoderma lucidum. Bioresour Technol 2009; 100: 1852-9.
20. Tang YJ, Zhang W, Zhu LW. Hyperproduction of Ganoderma polysaccharides and ganoderic acid during fermentation of medicinal mushroom Ganoderma lucidum by multi-stage control and induced culture. J Biosci Bioeng 2009; 108: S114-S34.
21. Zhang WX, Zhong JJ. Effect of oxygen concentration in gas phase on sporulation and individual ganoderic acids accumulation in liquid static culture of Ganoderma lucidum. J Biosci Bioeng 2010; 109: 37-40.
22. Papinutti L. Effects of nutrients, pH and water potential on exopolysaccharides production by a fungal strain belonging to Ganoderma lucidum complex. Bioresour Technol 2010; 101: 1941-6.
23. Zhao W, Xu JW, Zhong JJ. Enhanced production of ganoderic acids in static liquid culture of Ganoderma lucidum under nitrogenlimiting conditions. Bioresour Technol 2011; 102: 8185-90.
24. Misaki, A., Sone, Y., Yoshida, M., Takeuchi, K. Beta-glucan, its production and use. JP60188402 (1985).
25. Yamazaki, A. Method of cultivating mycelium of basidiomycetes. JP61234776 (1986).
26. Tsunoo, H., Kino, K., Yamasita, A. Novel glycoprotein, production process thereof and immunosuppressive agent containing same as effective ingredient. EP0288959 (1988).
27. Murata, T., Ishigami, Y., Ishikawa, H. Mucilaginous polysaccharide substance and production thereof. JP1121302 (1989).
28. Tsujikura, Y., Higuchi, T., Miyamoto, Y., Sato, S. Production of ganoderic acids. JP4304890 (1992).
29. Zore, I., Berovic, M., Boh, B., Hodzar, D., Pohleven, F. Procedure for preparation of inoculum for growing of fungus Ganoderma lucidum by submersion fermentation. SI9700014 (1998).
30. Li, B. J., Li, Q. S., Li, G. Ganoderma lucidum 10 ton tank fermentation technology. CN1188801 (1998).
31. Kosuna, K.-I., Yuan, L., Miura, T., Sun, B. Novel substance originating in basidiomycete culture, process for producing the same and use thereof. EP1154022 (2001).
32. Song, C. H., Yang, B. G. Method for preparing exo-polymers from mycelial culture of Ganoderma lucidum (KCTC 10241BP) and the use thereof. KR20030097062 (2003).
33. Yao, Q., Gao, X., Gong, Z., Ren, P., Han, J., Ren, H., Liu, Y., Zhao, J., Qu, L., Li, J. Liquid fermentation method for improving yield of Ganoderma lucidum triterpenoid by using rare earth element. CN101892282 (2010).
34. Yao, Q., Gao, X., Gong, Z., Ren, P., Ren, H. Han, J., Liu, Y., Li, J., Qu, L., Zhao, J. Liquid fermentation method capable of improving yield of Ganoderma lucidum polysaccharide. CN101880700 (2010).
35. Mikhajlovna, K. L., Vitalevna, A. A., Ilinichna, L. E. M., Petrovich, T. V., Vladimirovna, S. T., Mikhajlovich, B. V., Mikhajlovna, T. E. Method For Producing Agent Showing Anti-Cancer Activity, And Agent Produced By This Method. RU2416418 (2011).
36. Petre, M., Teodorescu, A. Process for cultivating macromycetes of the species Ganoderma lucidum and nourishing fungal biomass. RO126278 (2011).
37. Mizuno T, Wang G, Zhang J, Kawagishi H, Nishitoba T, Li J. Reishi, Ganoderma lucidum and Ganoderma tsugae: Bioactive substance and medicinal effects. Food Rev Int 1995; 11: 151-66.
38. Miyahara R, Yoshimoto T, Asawa K. Chemical structures and changes of extracts during growth of reishi (Ganoderma lucidum). Mokuzai Gakkaishi 1987; 33: 416-22.
39. Chan K. Linking chemical and biological characteristics in assuring the quality of Chinese medicinal materials and OTC products. Ganoderma: Genetics, chemistry, pharmacology and therapeutics, Proceedings of International symposium on Ganoderma research. Shanghai, China: October 21-23, 2002.
40. Chen XL, Liu XC, Sheng DP, Huang DK, Li WZ, Wang X. Distinction of broken cellular wall Ganoderma lucidum spores and G. lucidum spores using FTIR microspectroscopy. Spectrochim Acta-A Mol Miomol Spectrosc 2012; 97: 667-72.
41. Chen Y, Xie MY, Zhang H, Wang YX, Nie SP, Li C. Quantification of total polysaccharides and triterpenoids in Ganoderma lucidum and Ganoderma atrum by near infrared spectroscopy and chemometrics. Food Chem 2012; 135: 268-75.
42. 13C NMR detection in HPLC hyphenation mode: Analysis of Ganoderma lucidum terpenoids. J Nat Prod 2012; 75: 876-82.
43. Hirotani M, Ino C, Furuya T, Shiro M. Ganoderic acids T, S, and R, new triterpenoids from the cultured media of Ganoderma lucidum. Chem Pharm Bull 1986; 34: 2282-5.
44. Kikuchi T, Kanomi S, Murai Y, Kadota S, Tsubono K, Ogita Z. Constituents of the fungus Ganoderma lucidum (Fr.) Karst. I. Structures of ganoderic acids C2, E, I, and K, lucidenic acid F and related compounds. Chem Pharm Bull 1986; 34: 3695-712.
45. Morigiwa A, Kitabatake K, Fujimoto Y, Ikekawa N. Angiotensin converting enzyme inhibitory triterpenes from Ganoderma lucidum. Chem Pharm Bull 1986; 34: 3025-8.
46. Nishitoba T, Sato H, Sakamura S. Triterpenoids from the fungus Ganoderma lucidum. Phytochemistry 1987; 26: 1777-84.
47. Nishitoba T, Goto S, Sato H, Sakamura S. Bitter triterpenoids from the fungus Ganoderma applanatum. Phytochemistry 1989; 28: 193-7.
48. Lin LJ, Shiao MS. Seven new triterpenes from Ganoderma lucidum. J Nat Prod 1988; 51: 918-24.
49. Lin LJ, Shiao MS, Yeh SF. Triterpenes from Ganoderma lucidum. Phytochemistry 1988; 27: 2269-71.
50. Shiao MS, Lin LJ, Yeh SF, Chou CS. Two new triterpenes of the fungus Ganoderma lucidum. J Nat Prod 1987; 50: 886-90.
51. Chairul, Tokuyama T, Hayashi Y, Nishizawa M, Tokuda H, Chairul SM, Hayashi Y. Applanoxidic acids A, B, C and D, biologically active tetracyclic triterpenes from Ganoderma applanatum. Phytochemistry 1991; 30: 4105-9.
52. Chairul, Hayashi Y, Chairul SM. Lanostanoid triterpenes from Ganoderma applanatum. Phytochemistry 1994; 35: 1305-8.
53. Boh B, Berovic M, Wraber B, Hodzar D, Habijanic J, Pohleven F, et al. Ganoderma lucidum (W. Curt.: Fr.) Lloyd and G. applanatum (Pers.) Pat. (Aphyllophoromycetideae) from Slovenian habitats: Cultivation, isolation, and testing of active compounds. Int J Med Mushrooms 2004; 6: 15-32.
54. Yang M, Wang X, Guan S, Xia J, Sun J, Guo H, Guo D. Analysis of triterpenoids in Ganoderma lucidum using liquid chromatography coupled with electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 2007; 18: 927-39.
55. Toth JO, Luu B, Ourisson G. Les acides ganoderiques T a Z: triterpenes cytotoxiques de Ganoderma lucidum (Polyporaceae). Tetrahedron Lett 1983; 24: 1081-4.
56. Gao JJ, Min BS, Ahn EM, Nakamura N, Lee HK, Hattori M. New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem Pharm Bull 2002; 50: 837-40.
57. Lin SB, Li CH, Lee SS, Kan LS. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activatedprotein kinases and G2-phase cell cycle arrest. Life Sci 2003; 72: 2381-90.
58. Wang JL, Li YB, Liu RM, Zhong JJ. A new ganoderic acid from Ganoderma lucidum mycelia. J Asian Nat Prod Res 2010; 12: 727-30.
59. Cheng CR, Li YF, Xu PP, Feng RH, Yang M, Guan SH, Guo DA. Preparative isolation of triterpenoids from Ganoderma lucidum by counter-current chromatography combined with pH-zone-refining. Food Chem 2012; 130: 1010-6.
60. Hattori, Y., Ri, G., Hatta, A. Extraction method of Ganoderma lucidum extract. JP2003235502 (2003).
61. Yang, X. H. Method for extracting antineoplastic components in Ganoderma triterpene. CN1546519 (2004).
62. Xu, Z. X. Technique for extracting triterpene substane of mycelium of Ganoderma lucidum. CN1563408 (2005).
63. Minto, R., Kennedy, E. Process for preparing delta-7, 9(11) steroids from Ganoderma lucidum and analogs thereof. WO2012044817 (2012).
64. Bao XF, Wang XS, Dong Q, Fang JN, Li XY. Structural features of immunologically active polysaccharides from Ganoderma lucidum. Phytochemistry 2002; 59: 175-81.
65. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002; 60: 258-74.
66. Chen JZ, Seviour R. Medicinal importance of fungal ß-(1-3), (1-6)-glucans. Mycol Res 2007; 111: 635-52.
67. Moradali MF, Mostafavi H, Ghods S, Hedjaroude GA. Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int Immunopharmacol 2007; 7: 701-24.
68. Guo L, Xie J, Ruan Y, Zhou L, Zhu H, Yun X, et al. Characterization and immunostimulatory activity of a polysaccharide from the spores of Ganoderma lucidum. Int Immunopharmacol 2009; 9: 1175-82.
69. Wang J, Zhang L. Structure and chain conformation of five watersoluble derivatives of a d-D-glucan isolated from Ganoderma lucidum. Carbohydr Res 2009; 344: 105-12.
70. Dong Q, Wang Y, Shi L, Yao J, Li J, Ma FL, et al. A novel watersoluble beta-D-glucan isolated from the spores of Ganoderma lucidum. Cabohydr Res 2012; 353: 100-5.
71. Li YQ, Fang L, Zhang KC. Structure and bioactivities of a galactose rich extracellular polysaccharide from submergedly cultured Ganoderma lucidum. Carbohydr Polym 2007; 68: 323-8.
72. Ye LB, Zhang JS, Yang Y, Zhou S, Liu YF, Tang QJ, et al. Structural characterisation of a heteropolysaccharide by NMR spectra. Food Chem 2009; 112: 962-6.
73. Wang J, Ma Z, Zhang L, Fang Y, Jiang F, Phillips GO. Structure and chain conformation of water-soluble heteropolysaccharides from Ganoderma lucidum. Carbohydr Polym 2009; 86: 844-51.
74. Pan D, Wang LQ, Chen CH, Teng BS, Wang CD, Xu ZX, et al. Structure characterization of a novel neutral polysaccharide isolated from Ganoderma lucidum fruiting bodies. Food Chem 2012; 135: 1097-103.
75. Habijanic J, Svagelj M, Berovic M, Boh B, Wraber B. Submerged and solid-state cultivation of bioactive extra-and intracellular polysaccharides of medicinal mushrooms Ganoderma lucidum (W. Curt.: Fr.) P. Karst. and Grifola frondosa (Dicks.: Fr.) S. F. Gray (Aphyllophoromycetideae). Int J Med Mushrooms 2009; 11: 409-18.
76. Berovic M, Habijanic J, Zore I, Wraber B, Hodzar D, Boh B, et al. Submerged cultivation of Ganoderma lucidum biomass and immunostimulatory effects of fungal polysaccharides. J Biotechnol 2003; 103: 77-86.
77. Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, et al. Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem 1989; 264: 472-8.
78. Tanaka S, Ko K, Kino K, Tsuchiya K, Yamashita A, Murasugi A, et al. Complete amino acid sequence of an immunomodulatory protein, ling zhi-8 (LZ-8). J Biol Chem 1989; 264: 16372-7.
79. Kino K, Sone T, Watanabe J, Yamashita TH, Miyajima H, Tsunoo H. Immunomodulator, LZ-8, prevents antibody-production in mice. Int J Immunopharmacol 1991; 13: 1109-15.
80. Van Der Hem LG, Van Der Vliet JA, Bocken CFM, Kino K, Hoitsma AJ, Tax WJM. Ling zhi-8 studies of a new immunomodulating agent. Transplantation 1995; 60: 438-43.
81. Yeh CH, Chen HC, Yang JJ, Chuang WI, Sheu F. Polysaccharides PS-G and protein LZ-8 from Reishi (Ganoderma lucidum) exhibit diverse functions in regulating murine macrophages and T lymphocytes. J Agric Food Chem 2010; 58: 8535-44.
82. Sun, F., Liang, C., Zhang, X. Use of rLZ-8 for the prevention or treatment of thrombocytopenia and a pharmaceutical composition comprising rLZ-8. WO2010135854 (2010).
83. Sun, F., Zhang, X. Recombinant Ganoderma lucidium immunomodulatory protein (rLZ-8) and uses thereof. US2011009597 (2011).
84. Zhou, X., Wang, X., Li, Q., Su, K., Cong, Y. Recombinant fungal immunomodulatory protein gene in Ganoderma lucidum, protein coded whereby and application thereof. CN102199201 (2011).
85. Wang HX, Ng TB, Chiu SW. A distinctive ribonuclease from fresh fruiting bodies of the medicinal mushroom Ganoderma lucidum. Biochem Biophys Res Commun 2004; 314: 519-22.
86. Tian YP, Zhang KC. Purification and characterization of a novel proteinase A inhibitor from Ganoderma lucidum by submerged fermentation. Enzyme Microb Technol 2005; 36: 357-61.
87. Wang HX, Ng TB. Ganodermin, an antifungal protein from fruiting bodies of the medicinal mushroom Ganoderma lucidum. Peptides 2006; 27: 27-30.
88. Zhang JS, Tang QJ, Zimmerman-Kordmann M, Reuter W, Fan H. Activation of B lymphocytes by GLIS, a bioactive proteoglycan from Ganoderma lucidum. Life Sci 2002; 71: 623-38.
89. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, Lin CH. Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: Functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 2002; 10: 1057-62.
90. Liu J, Yang F, Ye LB, Yang XJ, Timani KA, Zheng Y, et al. Possible mode of action of antiherpetic activities of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Ethnopharmacol 2004; 95: 256-72.
91. Thakur A, Rana M, Lakhanpal TN, Ahmad A, Khan MI. Purification and characterization of lectin from fruiting body of Ganoderma lucidum. Biochim Biophys Acta 2007; 1770: 1404-12.
92. Ye LB, Zhang JS, Ye XY, Tang QJ, Liu YF, Gong CY, et al. Structural elucidation of the polysaccharide moiety of a glycopeptide (GLPCW-II) from Ganoderma lucidum fruiting bodies. Carbohydr Res 2008; 343: 746-52.
93. Shi Y, Sun J, He H, Guo H, Zhang S. Hepatoprotective effects of Ganoderma lucidum peptides against D-galactosamine-induced liver injury in mice. J Ethnopharmacol 2008; 117: 415-9.
94. Ye L, Li J, Zhang J, Pan Y. NMR characterization for polysaccharide moiety of a glycopeptides. Fitoterapia 2010: 81: 93-6.
95. Lee, K. H., Chung, H., Lee, C. W., Chung, C. H. Ganoderma lucidium IY009 which produces proteoglycan (G009) having effect of enhancing antitumor immunity. EP0563383 (1993).
96. Lee, K. H., Chung, H., Lee, C. W., Chung, C. H. Proteoglycan (G 009) effective in enhancing antitumor immunity. EP0610499 (1994).
97. Tsunoo, H., Kino, K., Yamashita, A. Novel glycoprotein, production process thereof and immunosuppressive agent containing same as effective ingredient. EP0288959 (1988).
98. Tsunoo, H., Kino, K., Yamashita, A. Glycoprotein isolated from Ganoderma having immunosuppressive activity. US5334704 (1994).
99. Lin, Z. B., Lin, S. Q., Wang S. Z. Ganoderma lucidum polysaccharide protein and its preparing method and use. CN1629186 (2005).
100. Yu, A., Yu, J., Lin, K. I., Yang, W. B., Wong, C. H. Fungal immunostimulatory compositions. US2007231339 (2007).
101. Yu, A., Wong, C. H., Jan, J. T., Cheng, S. E. Y. Anti-viral effect of an extract of Ganoderma lucidum. US20080214442 (2008).
102. Liang, S. M., Chen, Y. P., Yang, W. B., Wong, C. H. Reishi F3 subfraction polysaccharides and methods of using same. US20090263897 (2009).
103. Wang, Y. Y., Khoo, K. H., Chen, S. T., Lin, C. C., Wong, C. H., Lin, C. H., Chen, H.-s., Tsai, Y.-f. Immuno-modulating antitumor activities of Ganoderma lucidum (Reishi) polysaccharides. US7560114 (2009).
104. Russell R, Paterson M. Ganoderma-A therapeutic fungal biofactory. Phytochemistry 2006; 67: 1985-2001.
105. Ziegenbein FC, Hanssen HP, Konig WA. Secondary metabolites from Ganoderma lucidum and Spongiporus leucomallellus. Phytochemistry 2006; 67: 202-11.
106. Gao P, Hirano T, Chen Z, Yasuhara T, Nakata Y, Sugimoto A. Isolation and identification of C-19 fattyacids with anti-tumor activity from the spores of Ganoderma lucidum (Reishi mushroom). Fitoterapia 2012; 83: 490-9.
107. Liu X, Wang JH, Yuan JP. Pharmacological and anti-tumor activities of Ganoderma spores processed by top-down approaches. J Nanosci Nanotechnol 2005; 5: 2001-2013.
108. Xie YZ, Li SZ, Yee A, La Pierre DP, Deng ZQ, Lee DY, et al. Ganoderma lucidum inhibits tumour cell proliferation and induces tumour cell death. Enzyme Microb Technol 2006; 40: 177-85.
109. Fukuzawa M, Yamaguchi R, Hide I, Chen ZQ, HiraiY, Sugimoto A, et al. Possible involvement of long chain fatty acids in the spores of Ganoderma lucidum (Reishi Houshi) to its anti-tumor activity. Biol Pharm Bull 2008; 31: 1933-7.
110. Zhang JP, Zheng LM, Wang JH, Magnusson KE, Liu X. Lipid extract from completely sporoderm-broken germinating Ganoderma sinensis spores elicits potent antitumor immune responses in human macrophages. Phytother Res 2009; 23: 844-50.
111. Zhao H, Zhang QY, Zhao L, Huang X, Wang JC, Kang XM. Spore powder of Ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy: A pilot clinical trial. Evid Based Complement Alternat Med 2012; Art. No. 809614. doi: 10. 1155/2012/809614.
112. Liu, X., Chung, C. K. Germination-activated red Ganoderma lucidum spores and method for producing the same. EP1092765 (2001).
113. Chung, C. K., Tong, S. K. Ganoderma lucidum spores for treatment of autoimmune diseases. US20030143246 (2003).
114. Kosuna, K. C., Yuan, L., Miura, T., Sun, B. Substance derived from basidiomycetes culture, method for producing it and its use. US7883708 (2011).
115. Boh B, Berovic M, Zhang JS, Lin ZB. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007; 13: 265-301.
116. Min BS, Gao JJ, Nakamura N, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells. Chem Pharm Bull 2000; 48: 1026-33.
117. Gao JJ, Min BS, Ahn EM, Nakamura N, Lee HK, Hattori M. New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells. Chem Pharm Bull 2002; 50: 837-40.
118. Lin SB, Li CH, Chen YR, Kan LS, Lee SS. Triterpene extract from Ganoderma lucidum inhibits growth of hepatoma Huh7 cells: Involvement of oxidative stress induction. Ganoderma: Genetics, chemistry, pharmacology and therapeutics. Proceedings of International symposium on Ganoderma research. Shanghai, China: October 21-23, 2002.
119. Kimura Y, Taniguchi M, Baba K. Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: Mechanism of action and isolation of an active substance. Anticancer Res 2002; 22: 3309-18.
120. Lin SB, Li CH, Lee SS, Kan LS. Triterpene-enriched extracts from Ganoderma lucidum inhibit growth of hepatoma cells via suppressing protein kinase C, activating mitogen-activatedprotein kinases and G2-phase cell cycle arrest. Life Sci 2003; 72: 2381-90.
121. Yu SP, Zhang JS, Tang QJ, Shi XM, Liu YF, Yan Y, et al. Correlation between intracellular triterpenes from mycelia of Ganoderma lucidum in different growth stages and inhibition effect on tumor cells. Mycosystema 2004; 23: 548-54.
122. Liu GQ, Zhang KC. Mechanisms of the anti-cancer action of Ganoderma lucidum (Leyss. ex Fr.) Karst: A new understanding. J Integr Plant Biol 2005; 47: 129-35.
123. Mueller CI, Kumagai T, Kelly JO, Seeram NP, Heber D, Koeffler HP. Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res 2006; 30: 841-8.
124. Tang W, Liu HW, Zhao WM, Wei DZ, Zhong JJ. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci 2006; 80: 205-11.
125. Guan SH, Xia JM, Yang M, Wang XM, Liu X, Guo DA. Cytotoxic lanostanoid triterpenes from Ganoderma lucidum. J Asian Nat Prod Res 2008; 10: 695-700.
126. Yuen JWM, Gohel MDJ. The dual roles of Ganoderma antioxidants on urothelial cell DNA under carcinogenic attack. J Ethnopharmacol 2008; 118: 324-30.
127. Chen NH, Liu JW, Zhong JJ. Ganoderic acid Me inhibits tumor invasion through down-regulating matrix metalloproteinases 2/9 gene expression. J Pharmacol Sci 2008; 108: 212-6.
128. Yue QX, Song XY, Ma C, Feng LX, Guan SH, Wu WY, et al. Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells. Phytomedicine 2010; 17: 606-13.
129. Thyagarajan A, Jedinak A, Nguyen H, Terry C, Baldridge LA, Jiang J, et al. Triterpenes from Ganoderma lucidum induce autophagy in colon cancer through the inhibition of p38 mitogenactivated kinase (p38 MAPK). Nutr Cancer 2010; 62: 630-40.
130. Liu RM, Li YB, Zhong JJ. Ganoderic acid Mf and S induce mitochondria mediated apoptosis in human cervical carcinoma HeLa cells. Phytomedicine 2011; 18: 349-55.
131. Liu RM, Li YB, Zhong JJ. Anti-proliferation and induced mitochondria-mediated apoptosis of ganoderic acid Mk from Ganoderma lucidum mycelia in cervical cancer HeLa cells. Lat Am J Pharm 2012; 31: 43-50.
132. Wu GS, Lu JJ, Guo JJ, Li YB, Tan W, Dang YY, et al. Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Fitoterapia 2012; 83: 408-14.
133. Akihisa T, NakamuraY, Tagata M, Tokuda H, Yasukawa K, Uchiyama E, et al. Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum. Chem Biodiversity 2007; 4: 224-31.
134. Ko HH, Hung CF, Wang JP, Lin CN. Antiinflammatory triterpenoids and steroids from Ganoderma lucidum and G. tsugae. Phytochemistry 2008; 69: 234-9.
135. Dudhgaonkar S, Thyagarajan A, Sliva D. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol 2009; 9: 1272-80.
136. Kohda H, Tokumoto W, Sakamoto K, Fujii M, Hirai Y, Yamasaki K, et al. The biologically active constituents of Ganoderma lucidum (Fr.) Karst histamine release-inhibitory triterpenes. Chem Pharm Bull 1985; 33: 1367-74.
137. El-Mekkawy S, Meselhy MR, Nakamura N, Tezuka Y, Hattori M, Kakiuchi N, et al. Anti-HIV-1 and anti-HIV-1 protease substances from Ganoderma lucidum. Phytochemistry 1998; 49: 1651-7.
138. Min BS, Nakamura N, Miyashiro H, Bae KW, Hattori M. Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease. Chem Pharm Bull 1998; 46: 1607-12.
139. Iwatsuki K, Akihisa T, Tokuda H, Ukiya M, Oshikubo M, KimuraY, et al. Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation. J Nat Prod 2003; 66: 1582-5.
140. Lakshmi B, Ajith TA, Jose N, Janardhanan KK. Antimutagenic activity of methanolic extract of Ganoderma lucidum and its effect on hepatic damage caused by benzo[a]pyrene. J Ethnopharmacol 2006; 107: 297-303.
141. Pillai TG, John M, Thomas GS. Prevention of cisplatin induced nephrotoxicity by terpenes isolated from Ganoderma lucidum occurring in Southern parts of India. Exp Toxicol Pathol 2011; 63: 157-60.
142. Hajjaj H, Mace C, Roberts M, Niederberger P, Fay LB. Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors. Appl Environ Microbiol 2005; 71: 3653-8.
143. Kim SD. Isolation and structure determination of a cholesterol esterase inhibitor from from Ganoderma lucidum. J Microbiol Biotechnol 2010; 20: 1521-3.
144. Wang CN, Chen JC, Shiao MS, Wang CT. The aggregation of human platelet induced by ganodermic acid S. Biochim Biophys Acta 1989; 986: 151-60.
145. Su CY, Shiao MS, Wang CT. Predominant inhibition of ganodermic acid S on the thromboxane A2-dependent pathway in human platelets response to collagen. Biochim Biophys Acta 1999; 1437: 223-34.
146. Su CY, Shiao MS, Wang CT. Potentiation of ganoderemic acid S on prostaglandin E(1)-induced cyclic AMP elevation in human platelets. Thrombosis Res 2000; 99: 135-45.
147. Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, Kurashiki K, et al. Anti-androgenic activities of the triterpenoids fraction of Ganoderma lucidum. Food Chem 2007; 100: 1691-6.
148. Liu J, Shimizu K, Konishi F, Kumamoto S, Kondo R. The antiandrogen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum. Bioorg Med Chem 2007; 15: 4966-72.
149. Takashita, T., Yamashita, A., Ishihara, T. Neovascularization inhibitor. JP2004196761 (2004).
150. Watson, S., Muir, K., Kumari, R., Fang, L. Y., Guo, D. A. Compositions comprising Ganoderma lucidum extracts and uses thereof. WO2009087368 (2009).
151. Xu ZT, Chen XU, Zhong ZF, Chen LD, Wang YT. Ganoderma lucidum polysaccharides: Immunomodulation and potential antitumor activities. Am J Chin Med 2011; 39: 15-27.
152. Camargo MR, Kaneno RR. Antitumor properties of Ganoderma lucidum polysaccharides and terpenoids. Annu Rev Biomed Sci 2011; 13: 1-8.
153. Lee SS, Chen FD, Chang SC, Wei YH, Liu I, Chen C. In vivo antitumor effect of crude extracts from the mycelium of Ganoderma lucidum. J Chin Oncol Soc 1984; 5: 22-7.
154. Hwang SF, Liu KJ, KuanYH, Tung KS, Su CH, Tung TC. The inhibitory effect on artificial pulmonary metastasis of murine S-180 Sarcoma cells by orally administered Ganoderma lucidum. J Chin Oncol Soc 1989; 5: 10-5.
155. Furusawa E, Chou SC, Furasawa S, Hirazum A, Dang Y. Antitumor activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted Lewis lung carcinoma in synergeneic mice. Phytother Res 1992; 6: 300-4.
156. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. Prevention of development of N, N-dimethylhydrazine-induced colon tumors by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male ICR mice. Int J Mol Med 2002; 9: 113-7.
157. Liu X, Yuan JP, Chuang CK, Chen XJ. Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum. Cancer Lett 2002; 182: 155-61.
158. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep 2003; 10: 375-9.
159. Gao YH, Gao H, Chan E, Tang WB, Xu AL, Yang HY, et al. Antitumor activity and underlying mechanisms of Ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunol Invest 2005; 34: 171-98.
160. Pang X, Chen Z, Gao X, Liu W, Slavin M, Yao W, et al. Potential of a novel polysaccharide preparation (GLPP) from Anhui-grown Ganoderma lucidum in tumor treatment and immunostimulation. J Food Sci 2007; 72: S435-S42.
161. Li N, Hu YL, He CX, Hu CJ, Zhou J, Tang GP, et al. Preparation, characterisation and anti-tumour activity of Ganoderma lucidum polysaccharide nanoparticles. J Pharm Pharmacol 2010; 62: 139-44.
162. Zhang J, Tang Q, Zhou C, Jia W, Silva L, Nguyen LD, et al. GLIS, a bioactive proteoglycan fraction from Ganoderma lucidum, displays anti-tumour activity by increasing both humoral and cellular immune response. Life Sci 2010; 87: 628-37.
163. Shang DJ, Li Y, Wang C, Wang XM, Yu Z, Fu X. A novel polysaccharide from Se-enriched Ganoderma lucidum induces apoptosis of human breast cancer cells. Oncol Rep 2011; 25: 267-72.
164. Zhang J, Liu YJ, Park HS, Xia YM, Kim GS. Antitumor activity of sulfated extracellular polysaccharides of Ganoderma lucidum from the submerged fermentation broth. Carbohydr Polym 2012; 87: 1539-44.
165. Liu YJ, Shen J, Xia YM, Zhang J, Park HS. The polysaccharides from Ganoderma lucidum: Are they always inhibitors on human hepatocarcinoma cells? Carbohydr Polym 2012; 90: 1210-5.
166. Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, et al. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 1997; 70: 699-705.
167. Hu YH, Lin ZB. Polysaccharides isolated from mycelia of Ganoderma lucidum induced HL-60 cell apoptosis by enhancing macrophage activity. Chin Pharmacol Bull 1999; 5: 27-30.
168. Lei LS, Li MC, Sun LS. Ganoderma lucidum and its components on the function of macrophages. Ganoderma: Genetics, chemistry, pharmacology and therapeutics. Proceedings of International Symposium on Ganoderma Research. Shanghai, China: October 21-23, 2002.
169. Cao LZ, Lin ZB. Comparison of the effects of polysaccharides from wood-cultured and bag-cultured Ganoderma lucidum on murine spleen lymphocyte proliferation in vitro. Acta Pharmacol Sin 2003; 38: 92-7.
170. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, Lin CH. Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: Functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 2002; 10: 1057-62.
171. Lee SS, Lee PL, Chen CF, Wang SY, Chen KY. Antitumor effects of Ganoderma lucidum. Ganoderma: Genetics, chemistry, pharmacology and therapeutics. Proceedings of International Symposium on Ganoderma Research. Shanghai, China: October 21-23, 2002.
172. Cao LZ, Lin ZB. Regulation of Ganoderma lucidum polysaccharides on cytotoxic T lymphocytes induced by dendric cells in vitro. Ganoderma: Genetics, chemistry, pharmacology and therapeutics. Proceedings of International Symposium on Ganoderma Research. Shanghai, China: October 21-23, 2002.
173. Cao LZ, Lin ZB. Regulation on maturation and function of dendritic cells by Ganoderma lucidum polysaccharides. Immunol Lett 2002; 83: 163-9.
174. Boh B, Berovic M, Wraber B, Hodzar D, Habijanic J, Pohleven F, et al. Ganoderma lucidum (W. Curt.: Fr.) Lloyd and G. applanatum (Pers.) Pat. (Aphyllophoromycetideae) from Slovenian habitats: Cultivation, isolation, and testing of active compounds. Int J Med Mushrooms 2004; 6: 15-32.
175. Chen HS, Tsai YF, Lin S, Lin CC, Khoo KH, Lin CH, et al. Studies on the immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg Med Chem 2004; 12: 5595-601.
176. Zhu XL, Lin ZB. Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells. Acta Pharmacol Sin 2005; 26: 1130-7.
177. Zhu XL, Lin ZB. Modulation of cytokines production, granzyme B and perforin in murine CIK cells by G. lucidum polysaccharides. Carbohydr Polym 2006; 63: 188-97.
178. Cheng KC, Huang HC, Chen JH, Hsu JW, Cheng HC, Ou CH, et al. Ganoderma lucidum polysaccharides in human monocytic leukemia cells: From gene expression to network construction. BMC Genomics 2007; 8: 411.
179. Lai CY, Hung JT, Lin HH, Yu AL, Chen SH, Tsai YC, et al. Immunomodulatory and adjuvant activities of a polysaccharide extract of Ganoderma lucidum in vivo and in vitro. Vaccine 2010; 28: 4945-54.
180. Meng JJ, Hu XF, Shan FP, Hua H, Lu CL, Wang EH, et al. Analysis of maturation of murine dendritic cells (DCs) induced by purified Ganoderma lucidum polysaccharides (GLPs). Int J Biol Macromol 2011; 49: 693-9.
181. Cao QZ, Lin ZB. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci 2006; 78: 1457-63.
182. Song YS, Kim SH, Sa JH, Jin C, Lim CL, Park EH. Antiangiogenic and inhibitory activity on inducible nitric oxide production of the mushroom Ganoderma lucidum. J Ethnopharmacol 2004; 90: 17-20.
183. Stanley G, Harvey K, Slivova V, Jiang J, Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-1 from prostate cancer cells. Biochem Biophys Res Commun 2005; 330: 46-52.
184. 2-induced oxidative damage to cellular DNA. Teratog Carcinog Mutagen 2002; 22: 103-11.
185. Pillai TG, Nair CKK, Janardhanan KK. Enhancement of repair of radiation induced DNA strand breaks in human cells by Ganoderma mushroom polysaccharides. Food Chem 2010; 119: 1040-3.
186. You YH, Lin ZB. Protective effects of Ganoderma lucidum polysaccharides peptide on injury of macrophages induced by reactive oxygen species. Acta Pharmacol Sin 2002; 23: 787-91.
187. Zhang HN, He JH, Yuan L, Lin ZB. In vitro and in vivo protective effect of Ganoderma lucidum polysaccharides on alloxan-induced pancreatic islets damage. Life Sci 2003; 73: 2307-19.
188. Lai CSA, Yu MS, Yuen WH, So KF, Zee SY, Chang RCC. Antagonizing-amyloid peptide neurotoxicity of the anti-aging fungus Ganoderma lucidum. Brain Res 2008; 1190: 215-24.
189. Lei L, Lin Z, Chen Q, Li R, He Y. Antagonistic effect of Ganoderma lucidum polysaccharide on the immunosuppressive response induced by cyclosporin A, hydrocortisone and antitumor agents. Chin J Biotechnol Toxicol 1993; 7: 183-5.
190. Zhu XL, Chen A F, Lin ZB. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol 2007; 111: 219-26.
191. Li M, Lei L, Liang D. Effect of Ganderma polysaccharide on intracellular free calcium in murine peritoneal macrophages. Chin Pharm J 1999; 34: 805-7.
192. Sadava D, Still DW, Mudry RR, Kane SE. Effect of Ganoderma on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells. Cancer Lett 2009; 277: 182-9.
193. Tu, T. R., Li, C. F., Su, S. H., Wong, C. H., Fan, E. Compositions and methods for treating allergies, auto-immune diseases, and improving skin condition by Ganoderma lucidum (Reishi) polysaccharides. US20090060939 (2009).
194. Tu, T. R., Li, C. F., Su, S. H., Wong, C. H., Fan, E. Compositions and methods for treating psoriasis by Ganoderma lucidum (Reishi) polysaccharides. US20090060940 (2009).
195. Nwanneka OL, Ogbe AO, Olufunke O. Effect of the mycelial culture of Ganoderma lucidum on human pathogenic bacteria. Int J Biol 2011; 3: 111-4.
196. Fujiwara, H., Sawai, K. Antimicrobial agent for Staphylococcus comprising an extract of Ganoderma lucidum. EP0591603 (1994).
197. Wachtel-Galor, S., Benzie, I. F. F., Boost, M. V. Methods of reducing minimal inhibitory concentration of antibiotics and compositions resulting therefrom. US20070059321 (2007).
198. Kim HW, Shim J, Cho EC, Kim BK. Inhibition of cytopathic effect of human immunodeficiency virus-1 by water-soluble extract of Ganoderma lucidum. Arch Pharmacal Res 1997; 20: 425-31.
199. Stamets, P. Antiviral activity from medicinal mushrooms. US20060171958 (2006).
200. Lam FFY, Ko IWM, Ng ESK, Tam LS, Leung PC, Li EKM. Analgesic and anti-arthritic effects of Lingzhi and San Miao San supplementation in a rat model of arthritis induced by Freund's complete adjuvant. J Ethnopharmacol 2008; 120: 44-50.
201. Jia J, Zhang JJ, Hu YS, Wu Y, Wang QZ, Li NN, et al. Evaluation of in vivo antioxidant activities of Ganoderma lucidum polysaccharides in STZ-diabetic rats. Food Chem 2009; 115: 32-6.
202. Seto SW, Lam TY, Tam HL, Au ALS, Chan SW, Wu J, et al. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 2009; 16: 426-36.
203. Ping CX, Yan C, Bing LS, Guo CY, Yun LJ, Ping LL. Free radical scavenging of Ganoderma lucidum polysaccharides and its effect on antioxidant enzymes and immunity activities in cervical carcinoma rats. Carbohydr Polym 2009; 77: 389-93.
204. Guo CY, Ji SZ, Ping CX. Modulatory effect of Ganoderma lucidum polysaccharides on serum antioxidant enzymes activities in ovarian cancer rats. Carbohydr Polym 2009; 78: 258-62.
205. Heleno SA, Barros L, Martins A, Queiroz MJRP, Santos-Buelga C, Ferreira ICFR. Fruiting body, spores and in vitro produced mycelium of Ganoderma lucidum from Northeast Portugal: A comparative study of the antioxidant potential of phenolic and polysaccharidic extracts. Food Res Int 2012; 46: 135-40.
206. Fan LP, Li JW, Deng KQ, Ai LZ. Effects of drying methods on the antioxidant activities of polysaccharides extracted from Ganoderma lucidum. Carbohydr Polym 2012; 87: 1849-54.
207. Chan, B. P., Zhang, R. P. Neuroprotective Ganoderma compositions and methods of use. US20100278855 (2010).
208. Akikuni, Y. Therapeutic agent for a cancer and method of screening the same, and health-care auxillary food. US20030064076 (2003).
209. Yagita, A. Y. Anti-cancer compositions. US20030118606 (2003).
210. Wu, R. T. Polysaccharide-based extract from Ganoderma, pharmaceutical use thereof, and process for preparing the same. US6613754 (2003).
211. Kosuna, K. C., Yuan, L., Miura, T., Sun, B. Substance derived from basidiomycetes culture, method for producing it and its use. US7883708 (2011).
212. Vincent ECO, Fang L. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 2000; 7: 715-29.
213. Ye LB, Zheng XL, Zhang JS, Yang Y, Meng YC, Li JR, et al. Composition analysis and immunomodulatory capacity of peptidoglycan from Ling zhi or Reishi medicinal mushroom, Ganoderma lucidum (W. Curt.: Fr.) P. Karst. strain 119 (Aphyllophoromycetideae). Int J Med Mushrooms 2010; 2: 157-65.
214. Tsai CC, Yang FL, Huang ZY, Chen CS, Yang YL, Hua KF, et al. Oligosaccharide and peptidoglycan of Ganoderma lucidum activate the immune response in human mononuclear cells. J Agric Food Chem 2012; 60: 2830-7.
215. Cao QZ, Lin ZB. Antitumor and anti-angiogenic activity of Ganoderma lucidum polysaccharides peptide. Acta Pharmacol Sin 2004; 25: 833-8.
216. Liang CY, Li HR, Zhou H, Zhang SQ, Liu ZY, Zhou QL, et al. Recombinant LZ-8 from Ganoderma lucidum induces endoplasmic reticulum stress-mediated autophagic cell death in SGC-7901 human gastric cancer cells. Oncol Rep 2012; 27: 1079-89.
217. Ho YW, Yeung JSL, Chin PKY, Tang WM, Lin ZB, Man RYK, et al. Ganoderma lucidum polysaccharide peptide reduced the production of proinflammatory cytokines in activated rheumatoid synovial fibroblast. Mol Cell Biochem 2007; 301: 173-9.
218. Eo SK, Kim YS, Lee CK, Han SS. Possible mode of antiviral activity of acidic protein bound polysaccharide isolated from Ganoderma lucidum on herpes simplex viruses. J Ethnopharmacol 2000; 72: 475-81.
219. He H, He JP, Sui YJ, Zhou SQ, Zhou SQ, Wang J. The hepatoprotective effects of Ganoderma lucidum peptides against carbon tetrachloride-inducedliver injury in mice. J Food Biochem 2008; 32: 628-41.
220. Sun J, He H, Xie BJ. Novel antioxidant peptides from fermented mushroom Ganoderma lucidum. J Agric Food Chem 2004; 52: 6646-52.
221. You YH, Lin ZB. Ganoderma lucidum polysaccharides peptide (GLPP) protects ECV304 cells from oxidantive injury. Acta Pharmacol Sin 2006; 27: 355-5.
222. Yuan BJ, Zhang WZ, Yu ZQ, Zhang RJ. In vitro evaluation of antioxidant property of the exopolysaccharides peptides from Ganoderma lucidum CAU5501 in submerged culture. J Food Agric Environ 2012; 10: 97-101.
223. Bishop, M., Bishop, E., Smith, W., Gillis, G. Anti-glycation hydrolysate of G. lucidum. US7524504 (2009).
224. Wong, K. P., Wong, M. C. Compositions containing an active fraction isolated from Ganoderma lucidum and methods of use. US2003095981 (2003).
225. Chu, C. L., Chen, T. C. Methods for enhancing innate and adaptive immunity and antigen immunogenicity. US20090285789 (2009).
226. Chu, C. L., Chen, T. C. Method for augmenting the immunogenicity of an antigen. US20110280906 (2011).
227. Wong, C.-H., Hsu, H.-Y., Hua, K.-F., Lin, C.-H., Hsu, J., Chen, S.-T., Lin, K.-I., Yang, W.-B., Yu, J., Yu, A. Methods and compositions associated with administration of an extract of Ganoderma lucidum. WO2006044616 (2006).
228. Wong, C.-H., Fan, E., Hsu, H.-Y., Tu, T.-R., Lin, W.-C., Li, C.-F., Weng, S.-T., Wang, W.-T. Reishi polysaccharide-based compositions and methods for treatment of cancer. WO2011133983 (2011).
229. Shiao, M.-S. Method for sensitizing cancer cells to cancer therapies with a mevalonate-reducing compound. US2002173538 (2002).
230. Wheatley, G. W., Chapman, T. B. A method for producing an extract from Ganoderma lucidum containing ganoderic acid. EP0943006 (2002).
231. Vittori, N. Method of isolating mucilaginous polysaccharides and uses thereof. US6482942 (2002).
232. Feng, P., Feng, M., Huang, J. S., Qian, Y. F., Shen, J., Chen, L., Wang, L. A. Process for refining Ganoderma spore polysacchoride. US20080112967 (2008).
233. Kristiansen, B. Immune modulating compounds from fungi. US7514085 (2009).
234. Hua, K. F., Hsu, H. Y., Wong, C. H. Methods and compositions associated with administration of an extract of Ganoderma lucidum. US7687064 (2010).
235. Liu, X., Huang, X.-N., Chung, P. C.-K. Method for extracting oleaginous substances from Ganoderma lucidum spores. EP1245235 (2004).
236. Chung, C. K., Tong, S. K. External preparation for skin containing oleaginous substances extracted from Ganoderma lucidum and method of using the same. US200501800988 (2005).
237. Gow, R. T., Li, D., Sypert, G. W., Alberte, R. S. Extracts and methods comprising Ganoderma species. US20080112966 (2008).
238. Shih, D. T. B., Chen, W. Y., Wong, C. H. Reishi-mediated enhancement of human tissue progenitor cell adhesion and differentiation. US20080247989 (2008).
239. Lu, E. S., Young J. Herbal composition for treating cancer. WO2010028075 (2010).
240. Wasser SP, Weiss AL. Medicinal mushrooms-Ganoderma lucidum, Reishi mushroom. Pedeifus Publishing House: Haifa 1997.
241. Chang ST, Buswell JA. Mushroom nutriceuticals. World J Microbiol Biotechnol 1996; 12: 473-6.
242. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS. Ganoderma lucidum: A potent pharmacological macrofungus. Curr Pharm Biotechnol 2009; 10: 717-42.
243. Wasser SP. Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol 2010; 89: 1323-32.
244. nd ed. Boca Raton (FL): CRC Press; 2011.
245. Chen, S., Wang, X. Herbal composition for treating prostate carcinoma. EP0977556 (2000).
246. Lam, P. Y. S. Herbal immune system stimulant. US6464982 (2002).
247. Chen, S. Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising prenyl flavonoids. WO2004080474 (2004).
248. Goino, T. Physiologically active compositions based upon active ingredients of basidiomycotina and araliaceae. WO0156589 (2001) & US 6746675 (2004).
249. Hattori, K., Mizutani, H., Osumi, K. Matrix metalloprotease inhibitor. EP1449534 (2004).
250. Cheung, D. C. L. Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject. WO2005112966 (2005).
251. Dao, J., Dao, T. C. S., Tong, D. D., Wilson, L., Jordan, M. A., Gerwick, W. Compositions of botanical extracts for cancer therapy. US20050208070 (2005).
252. Dao, J., Dao, J. J. Compositions of botanical extracts for treating malignancy-associated changes. US20050196409 (2005).
253. Mahajna, J. A., Yassin, M., Wasser, S. P. Mushroom extracts having anti-cancer activity. US20060057157 (2006).
254. Lu, E. S., Young J. Herbal composition for treating cancer. WO2010028075 (2010).
255. Soeda, S., Kuramoto, Y., Hayashida, S., Kosako, T., Urano, K., Honda, S., Motonagare, R., Nakaji, K. New anticancer agent or cancer prophylactic agent having both neovascularizationinhibiting effect and immune control effect with preparation or mixture of basidiomycetes belonging to polyporaceae and component of pinaceae plant. JP2011098922 (2011).
256. Kong, P. Ganoderma lucidum coffee and preparation method thereof. WO2011077295 (2011).
257. Feng, M., Shen, J. Ganoderma lucidum spore oil-containing Chinese medicinal composition with efficient cancer resistance. CN102379905 (2012).
258. Zhang CY, Li YM. Clinical investigation of Green Valley Lingzhi capsule on type 2 diabetes mellitus. Ganoderma: Genetics, chemistry, pharmacology and therapeutics, Proceedings of International Symposium on Ganoderma Research. Shanghai, China: October 21-23, 2002.
259. Shi KG, Quing LH. The follow-up observation assessment of medium and late phases cancer treated by Chinese Ganoderma lucidum essence (CGLE). Ganoderma: Genetics, Chemistry, Pharmacology and Therapeutics, Proceedings of International Symposium on Ganoderma Research. Shanghai, China: October 21-23, 2002.
260. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 2003; 32: 201-15.
261. Gao Y, Tang W, Dai X, Chen G, Ye J, Chen E, et al. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food 2005; 8: 159-68.
262. Noguchi M, Kakuma T, Tomiyasu K, Konishi F, Kumamoto S, Kondo R, et al. Phase I study of a methanol extract of Ganoderma lucidum, edible and medicinal mushroom, in men with mild symptoms of bladder outlet obstruction. Urology 2005; 66 (Suppl 3A): 21.
263. Chan WK, Lam DT, Law HK, Wong WT, Leung KMW, Lau YL, et al. Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. J Altern Complement Med 2005; 11: 1047-57.
264. Chen X, Hu ZP, Yang XX, Huang M, Gao Y, Tang W, et al. Monitoring of immune responses to a herbal immuno-modulator in pa tients with advanced colorectal cancer. Int Immunopharmacol 2006; 6: 499-508.
265. Noguchi M, Kakuma T, Tomiyasu K, Itoh K, Konishi F, Kumamoto S, et al. A randomized clinical trial of an ethanol extract of Ganoderma lucidum (edible and medicinal mushroom) in men with lower urinary tract symptoms. Urology 2007; 70 (Suppl 3A): 254.
266. Li EK, Tam LS, Wong CK, Li WC, Lam CWK, Wachtel-Galor S, et al. Safety and efficacy of Ganoderma lucidum (Lingzhi) and San miao San supplementation in patients with rheumatoid arthritis: A double-blind, randomized, placebo-controlled pilot trial. Arthritis Rheum-Arthritis Care Res 2007; 57: 1143-50.
267. Chen AW, Seleen J. Potential benefits of Ling Zhi or Reishi mushroom Ganoderma lucidum (W. curt.: Fr.) P. Karst. (Aphyllophoromycetideae) to breast cancer patients. Int J Med Mushrooms 2007; 9: 29-38.
268. Zhao H, Zhang QY, Zhao L, Huang X, Wang JC, Kang XM. Spore powder of Ganoderma lucidum improves cancer-related fatigue in breast cancer patients undergoing endocrine therapy: a pilot clinical trial. Evid Based Complement Alternat Med 2012; Art. No. 809614. doi: 10. 1155/2012/809614.
269. Chu TTW, Benzie IFF, Lam CWK, Fok BSP, Lee, KKC, Tomlinson B. Study of potential cardioprotective effects of Ganderma lucidum (Lingzhi): Results of a controlled human intervention trial. Br J Nutr 2012; 107: 1017-27.
270. Jin X, Beguerie JR, Sze DMY, Chan GCF. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev 2012; 6: CD007731. doi: 10. 1002/14651858. CD007731. pub2.
271. Yuen MF, Ip P, Ng WK, Lai CL. Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). J Hepatol 2004; 41: 685-90.
272. Wanmuang H, Leopairut J, Kositchaiwat C, Wananukul W, Bunyaratvej S. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai 2007; 90: 179-81.
273. Lin ZB, Zhang HN. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 2004; 25: 1387-95.
274. Liu GQ, Zhang KC. Mechanisms of the anti-cancer action of Ganoderma lucidum (Leyss. ex Fr.) Karst.: A new understanding. J Integr Plant Biol 2005; 47: 129-35.
275. Yuen JWM, Gohel MDI. Anti-cancer effects of Ganoderma lucidum: A review of scientific evidence. Nutr Cancer 2005; 53: 11-7.
276. Sliva D. Ganoderma lucidum in cancer research. Leuk Res 2006; 30: 767-8.